Vancomycin and linear IgA bullous dermatosis

  • Amr Ismail Departments of Internal Medicine at Texas Tech University Health Sciences Center, Lubbock, TX
  • Rocio Gavidia Quezada Departments of Internal Medicine at Texas Tech University Health Sciences Center, Lubbock, TX
  • Kenneth Iwuji Departments of Internal Medicine at Texas Tech University Health Sciences Center, Lubbock, TX
  • Abdussalam Shredi Departments of Internal Medicine at Texas Tech University Health Sciences Center, Lubbock, TX
  • Michelle Tarbox Dermatology at Texas Tech University Health Sciences Center, Lubbock, TX
Keywords: Vancomycin, methicillin-resistant Staphylococcus aureus, linear IgA bullous dermatosis, vancomycin skin reactions

Abstract

Vancomycin is a broad-spectrum antibiotic that is considered an optimal parenteral
treatment for many infections, including septicemia, pneumonia, cellulitis, endocarditis, and
meningitis caused by methicillin-resistant Staphylococcus aureus. It is the first-line treatment
for the increasing health care-associated infection Clostridium difficile pseudomembranous
colitis. More side effects are being reported secondary to increased vancomycin use. Of those
side effects, skin reactions are becoming more recognized by physicians.

References

VISA/VRSA–Vancomycin–Intermediate/Resistant Staphylococcus

aureus fact sheet. Available at: http://www.cdc.gov/

ncidod/hip/ARESIST/visa.htm.

Korman TM, Turnidge JD, Grayson ML. Risk factors for

adverse cutaneous reactions associated with intravenous vancomycin.

J Antimicrob Chemother 1997;39:315–318.

Jones DH. Early diagnosis is key in vancomycin-induced linear

IgA bullous dermatosis and Stevens-Johnson syndrome. J

Am Osteopath Assoc 2004 Apr; 104(4):157–63.

Fortuna G, Marinkovich MP. Linear immunoglobulin A bullous

dermatosis. Clin Dermatol 2012;30:38.

Minhas JS, Immune-mediated reactions to vancomycin: A

systematic case review and analysis. Ann Allergy Asthma

Immunol 2016 Jun 4; 116(6):544–53.

Lings K, Bygum A. Linear IgA bullous dermatosis: a retrospective

study of 23 patients in Denmark. Acta Derm Venereol

;95:466–471.

Published
2018-01-19
How to Cite
Ismail, A., Quezada, R. G., Iwuji, K., Shredi, A., & Tarbox, M. (2018). Vancomycin and linear IgA bullous dermatosis. The Southwest Respiratory and Critical Care Chronicles, 6(22), 38-41. https://doi.org/10.12746/swrccc.v6i22.445